Curcumin ameliorates doxorubicin-induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in rats

被引:128
作者
Benzer, Fulya [1 ]
Kandemir, Fatih Mehmet [2 ]
Ozkaraca, Mustafa [3 ]
Kucukler, Sefa [2 ]
Caglayan, Cuneyt [4 ]
机构
[1] Munzur Univ, Fac Engn, Dept Food Engn, Tunceli, Turkey
[2] Ataturk Univ, Fac Vet Med, Dept Biochem, Erzurum, Turkey
[3] Ataturk Univ, Fac Vet Med, Dept Pathol, Erzurum, Turkey
[4] Bingol Univ, Fac Vet Med, Dept Biochem, Bingol, Turkey
关键词
apoptosis; cardiotoxicity; curcumin; doxorubicin; inflammation; CHRYSIN PROTECTS; KAPPA-B; STRESS; ANTIOXIDANT; TOXICITY; CARDIOMYOPATHY; NEPHROTOXICITY; NEPHROPATHY; DISEASE; CANCER;
D O I
10.1002/jbt.22030
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Doxorubicin (DXR) is a highly effective drug for chemotherapy. However, cardiotoxicity reduces its clinical utility in humans. The present study aimed to assess the ameliorative effect of curcumin against DXR-induced cardiotoxicity in rats. Rats were subjected to oral treatment of curcumin (100 and 200mg/kg body weight) for 7 days. Cardiotoxicity was induced by single intraperitoneal injection of DXR (40mg/kg body weight) on the 5th day and the rats sacrificed on 8th day. Curcumin ameliorated DXR-induced lipid peroxidation, glutathione depletion, decrease in antioxidant (superoxide dismutase, catalase, and glutathione peroxidase) enzyme activities, and cardiac toxicity markers (CK-MB, LDH, and cTn-I). Curcumin also attenuated activities of Caspase-3, cyclooxygenase-2, inducible nitric oxide synthase, and levels of nuclear factor kappa-B, tumor necrosis factor-, and interleukin-1, and cardiac tissue damages that were induced by DXR. Moreover, curcumin decreased the expression of 8-OHdG and 3,3-dityrosine. This study demonstrated that curcumin has a multi-cardioprotective effect due to its antioxidant, anti-inflammatory, and antiapoptotic properties.
引用
收藏
页数:7
相关论文
共 45 条
[31]   Rutin ameliorates cyclophosphamide induced oxidative stress and inflammation in Wistar rats: Role of NFκB/MAPK pathway [J].
Nafees, Sana ;
Rashid, Summya ;
Ali, Nemat ;
Hasan, Syed Kazim ;
Sultana, Sarwat .
CHEMICO-BIOLOGICAL INTERACTIONS, 2015, 231 :98-107
[32]   ESTIMATION OF PRODUCT OF LIPID PEROZIDATION (MALONYL DIALDEHYDE) IN BIOCHEMICAL SYSTEMS [J].
PLACER, ZA ;
CUSHMAN, LL ;
JOHNSON, BC .
ANALYTICAL BIOCHEMISTRY, 1966, 16 (02) :359-&
[33]   Curcumin, a component of golden spice: From bedside to bench and back [J].
Prasad, Sandeo ;
Gupta, Subash C. ;
Tyagi, Amit K. ;
Aggarwal, Bharat B. .
BIOTECHNOLOGY ADVANCES, 2014, 32 (06) :1053-1064
[34]   Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats [J].
Rashid, Summya ;
Ali, Nemat ;
Nafees, Sana ;
Ahmad, Shiekh Tanveer ;
Arjumand, Wani ;
Hasan, Syed Kazim ;
Sultana, Sarwat .
TOXICOLOGY MECHANISMS AND METHODS, 2013, 23 (05) :337-345
[35]   Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-XL [J].
Reeve, Janice L. V. ;
Szegezdi, Eva ;
Logue, Susan E. ;
Chonghaile, Triona Ni ;
O'Brien, Timothy ;
Ritter, Thomas ;
Samali, Afshin .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2007, 11 (03) :509-520
[36]   ESTIMATION OF TOTAL PROTEIN-BOUND AND NONPROTEIN SULFHYDRYL GROUPS IN TISSUE WITH ELLMANS REAGENT [J].
SEDLAK, J ;
LINDSAY, RH .
ANALYTICAL BIOCHEMISTRY, 1968, 25 (1-3) :192-&
[37]   Curcumin in inflammatory diseases [J].
Shehzad, Adeeb ;
Rehman, Gauhar ;
Lee, Young Sup .
BIOFACTORS, 2013, 39 (01) :69-77
[38]   Curcumin in Cancer Chemoprevention: Molecular Targets, Pharmacokinetics, Bioavailability, and Clinical Trials [J].
Shehzad, Adeeb ;
Wahid, Fazli ;
Lee, Young Sup .
ARCHIV DER PHARMAZIE, 2010, 343 (09) :489-499
[39]   Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment [J].
Shuai, Yi ;
Guo, Jia-Bin ;
Peng, Shuang-Qing ;
Zhang, Li-Shi ;
Guo, Jun ;
Han, Gang ;
Dong, Yan-Sheng .
TOXICOLOGY LETTERS, 2007, 170 (01) :66-74
[40]  
Simunek T, 2009, PHARMACOL REP, V61, P154